The selective nature of the drug makes it preferable to other stress agents such as adenosine, which are less selective and therefore cause more side-effects. Regadenoson was approved by the United States Food and Drug Administration on April 10, 2008 and is marketed by Astellas Pharma under the tradename Lexiscan.
Human capital flight, sometimes called brain drain, refers to the emigration of intelligent, well-educated individuals for better pay or conditions, causing their places of origin to lose skilled people, or brains..
Brain drain can harm a nation's economy because the professionals that leave usually earn large salaries and are no longer spending money in their home country. Furthermore, the nation's overall expertise is diminished, which can result lower progress and education rates.